
Genmab A/S
CSE:GMAB

Intrinsic Value
The intrinsic value of one
GMAB
stock under the Base Case scenario is
2 563.98
DKK.
Compared to the current market price of 1 414 DKK,
Genmab A/S
is
Undervalued by 45%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Genmab A/S
Fundamental Analysis


Revenue & Expenses Breakdown
Genmab A/S
Balance Sheet Decomposition
Genmab A/S
Current Assets | 27.9B |
Cash & Short-Term Investments | 21.1B |
Receivables | 6.7B |
Other Current Assets | 62m |
Non-Current Assets | 18B |
Long-Term Investments | 228m |
PP&E | 1.9B |
Intangibles | 14.9B |
Other Non-Current Assets | 960m |
Free Cash Flow Analysis
Genmab A/S
DKK | |
Free Cash Flow | DKK |
Earnings Waterfall
Genmab A/S
Revenue
|
21.5B
DKK
|
Cost of Revenue
|
-985m
DKK
|
Gross Profit
|
20.5B
DKK
|
Operating Expenses
|
-13.5B
DKK
|
Operating Income
|
7.1B
DKK
|
Other Expenses
|
765m
DKK
|
Net Income
|
7.8B
DKK
|
GMAB Profitability Score
Profitability Due Diligence
Genmab A/S's profitability score is 79/100. The higher the profitability score, the more profitable the company is.

Score
Genmab A/S's profitability score is 79/100. The higher the profitability score, the more profitable the company is.
GMAB Solvency Score
Solvency Due Diligence
Genmab A/S's solvency score is 99/100. The higher the solvency score, the more solvent the company is.

Score
Genmab A/S's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
GMAB Price Targets Summary
Genmab A/S
According to Wall Street analysts, the average 1-year price target for
GMAB
is 2 278.38 DKK
with a low forecast of 1 445.31 DKK and a high forecast of 3 118.5 DKK.
Dividends
Current shareholder yield for GMAB is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
GMAB
stock under the Base Case scenario is
2 563.98
DKK.
Compared to the current market price of 1 414 DKK,
Genmab A/S
is
Undervalued by 45%.